IDEXX Laboratories, Inc. $IDXX Shares Sold by USA Financial Formulas

USA Financial Formulas lowered its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 44.3% during the fourth quarter, HoldingsChannel reports. The firm owned 2,077 shares of the company’s stock after selling 1,650 shares during the period. IDEXX Laboratories accounts for approximately 0.3% of USA Financial Formulas’ holdings, making the stock its 28th largest holding. USA Financial Formulas’ holdings in IDEXX Laboratories were worth $1,405,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Virtus Advisers LLC purchased a new stake in IDEXX Laboratories during the 3rd quarter worth $26,000. Park Place Capital Corp purchased a new position in IDEXX Laboratories in the 4th quarter valued at about $29,000. WealthCollab LLC purchased a new position in IDEXX Laboratories in the 2nd quarter valued at about $30,000. J.Safra Asset Management Corp acquired a new stake in shares of IDEXX Laboratories during the third quarter valued at about $31,000. Finally, Armstrong Advisory Group Inc. increased its position in shares of IDEXX Laboratories by 55.9% during the third quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock worth $34,000 after acquiring an additional 19 shares during the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $558.32 on Friday. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23. The company has a market capitalization of $44.40 billion, a price-to-earnings ratio of 42.72, a price-to-earnings-growth ratio of 3.39 and a beta of 1.66. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $769.98. The business has a 50 day simple moving average of $631.32 and a 200-day simple moving average of $661.91.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Monday, February 2nd. The company reported $3.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.93 by $0.15. The firm had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The firm’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same period last year, the business posted $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, equities research analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on IDXX. Barclays reduced their price target on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. UBS Group cut their price target on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a report on Tuesday, February 3rd. BTIG Research reduced their price objective on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a research note on Tuesday, February 3rd. Piper Sandler decreased their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a report on Monday, February 9th. Finally, Wall Street Zen downgraded shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Seven analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $783.33.

Insider Activity at IDEXX Laboratories

In related news, EVP George Fennell sold 11,345 shares of the business’s stock in a transaction dated Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the completion of the sale, the executive vice president owned 9,823 shares of the company’s stock, valued at $6,352,730.56. This represents a 53.60% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Nimrata Hunt sold 1,758 shares of the stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $634.57, for a total transaction of $1,115,574.06. Following the sale, the executive vice president owned 18,141 shares in the company, valued at approximately $11,511,734.37. This trade represents a 8.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 45,957 shares of company stock valued at $29,862,109 in the last ninety days. 0.98% of the stock is owned by insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.